Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

For better result, minimum character length is four(4)
Results 121 - 130 of 245 for gsk. (0.09 seconds)

CBT 200 Gives Up 40 Points. More details...
CBT 200 Off Almost 50 Points. More details...
Development Stage Biotech Is Well-Received. More details...
CBT 200 Drops 11 Points. More details...
CBT 200 Gains 14 Points. More details...
CBT 200 Adds on 1%. More details...
CBT 200 Closes Up 1.8%. More details...
CBT 200 Loses 12 Points. More details...
Advance Is Broad And Deep. More details...
Glaxo Seeks Approval For Leukemia Drug. More details...
prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | next
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital